Showing results (1351-1360 of 1,518) with videos related to

Sort By:
Pageof 152
The Annals of Thoracic Surgery|November 7, 2025
Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671Moishe Liberman, David R Jones, Heather Wakelee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)Stephen V Liu, Martin Reck, Aaron S Mansfield, et al.
JAMA Oncology|June 4, 2021
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized TrialSalma K Jabbour, Ki Hyeong Lee, Nikolaj Frost, et al.
Translational Lung Cancer Research|September 21, 2020
Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectivesSabine Wessels, Thomas Muley, Petros Christopoulos, et al.
ACS Infectious Diseases|March 13, 2019
IID572: A New Potentially Best-In-Class β-Lactamase InhibitorFolkert Reck, Alun Bermingham, Johanne Blais, et al.
The Lancet. Respiratory Medicine|March 30, 2019
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialMartin Reck, Tony S K Mok, Makoto Nishio, et al.
Nature Communications|December 3, 2025
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinationsTianshi Lu, Habib Hamidi, Mark A Socinski, et al.
Discover Oncology|October 3, 2023
Preliminary results from the EMoLung clinical study showing early lung cancer detection by the LC scoreKarla Rubio, Jason M Müller, Aditi Mehta, et al.
ESMO Open|February 14, 2018
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapyChristian Manegold, Alex Adjei, Federico Bussolino, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2022
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMAJordi Remon, Benjamin Lacas, Roy Herbst, et al.
Pageof 152